Table 3.
Multivariate Cox regression analysis of OS and PFS in training and validation cohorts
| Variables | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Training cohort | ||||
| EBV DNA (positive vs negative) | 1.891(1.874-4.090) | 0.015* | 1.513(1.859-2.664) | 0.050* |
| AJCC stage (8th) (IVA vs III) | 4.963(1.896-9.257) | 0.001* | 4.439(2.268-7.728) | 0.001* |
| SII (≥402.10 vs <402.10) | 3.732(1.447-9.627) | 0.006* | 3.366(1.976-9.649) | 0.001* |
| Validation cohort | ||||
| EBV DNA (positive vs negative) | 3.395(1.851-6.740) | 0.018* | 3.112(1.048-1.905) | 0.047* |
| AJCC stage (8th) (IVA vs III) | 4.972(1.086-13.843) | 0.037* | 4.661(1.172-3.578) | 0.012* |
| SII (≥402.10 vs <402.10) | 2.643(1.046-12.689) | 0.042* | 1.285(1.737-2.243) | 0.036* |
Note: *statistically significant.
SII: systemic immune-inflammation index; EBV DNA: Epstein-Barr virus DNA; AJCC: American Joint Committee on Cancer; OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval.